IBJNews

Lilly drug beats Roche’s Avastin in advanced colon cancer

Bloomberg News
September 30, 2013
Keywords
Back to TopCommentsE-mailPrintBookmark and Share

Cancer drug Erbitux extended the lives of patients with a form of advanced colon cancer more than seven months longer than those taking Roche Holding AG’s Avastin, manufacturer Merck KGaA of Germany said Saturday.

Merck sells the medicine outside North America. Indianapolis-based Eli Lilly and  Co. and New York-based Bristol-Myers Squibb Co. are the partners for the drug in the United States. Erbitux generated sales for Merck of $1.2 billion last year, while. Lilly realized about $400 million in revenue from the drug in 2012.

In a trial among 342 patients with advanced colon cancer lacking certain genetic mutations, those receiving Erbitux had a median survival of 33.1 months, compared with 25.6 months for those treated with Avastin, according to a Merck statement of data presented at a cancer conference in Amsterdam. Both drugs were combined with chemotherapy.

The findings suggest that Erbitux, already approved in Europe as a treatment for patients with so-called KRAS wild-type tumors, may have a role in a sub-group of patients with so-called RAS wild-type cancer. Merck, based in Darmstadt, Germany, is studying the results of two other trials for evidence of the same trend, with a view to seeking regulatory approval in Europe for the drug in patients with RAS wild-type cancer.

“Of course, we are highly interested to get the right treatment to the right patients,” Oliver Kisker, head of clinical development at Merck’s Serono unit, said. The additional 7.5 months is “very impressive, very interesting.”

Erbitux and Avastin are so-called monoclonal antibodies designed to block a protein that causes cancer cells to multiply. By coupling Erbitux or Avastin with a trio of cell-killing chemotherapy drugs, doctors aim both to stop tumors from growing and to shrink them.

Among the 16 percent of patients with a mutant form of RAS colon cancer, those who received Erbitux had a median overall survival of 20.3 months compared with 20.6 months for those who received Avastin, according to the Merck report.

The study missed its main goal of shrinking tumors more than Avastin did in patients with the mutant form of KRAS colon cancer, Merck said in June.

Lilly shares were down 14 cents Monday, to $50.36 each.

ADVERTISEMENT

  • good news
    I like hearing this news, if accurate, 7.5 months is a long time when one is facing death! Avastin has been tried on so many types of cancer, and it has seemed to provide very little to no benefit for any, and its side effects can be devastating. Unfortunately, Avastin cost so much to develop they won't just quit trying it and come up with a better cancer drug. Now it seems they will throw it at any cancer to see if it sticks.

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. Those of you yelling to deport them all should at least understand that the law allows minors (if not from a bordering country) to argue for asylum. If you don't like the law, you can petition Congress to change it. But you can't blindly scream that they all need to be deported now, unless you want your government to just decide which laws to follow and which to ignore.

  2. 52,000 children in a country with a population of nearly 300 million is decimal dust or a nano-amount of people that can be easily absorbed. In addition, the flow of children from central American countries is decreasing. BL - the country can easily absorb these children while at the same time trying to discourage more children from coming. There is tension between economic concerns and the values of Judeo-Christian believers. But, I cannot see how the economic argument can stand up against the values of the believers, which most people in this country espouse (but perhaps don't practice). The Governor, who is an alleged religious man and a family man, seems to favor the economic argument; I do not see how his position is tenable under the circumstances. Yes, this is a complicated situation made worse by politics but....these are helpless children without parents and many want to simply "ship" them back to who knows where. Where are our Hoosier hearts? I thought the term Hoosier was synonymous with hospitable.

  3. Illegal aliens. Not undocumented workers (too young anyway). I note that this article never uses the word illegal and calls them immigrants. Being married to a naturalized citizen, these people are criminals and need to be deported as soon as humanly possible. The border needs to be closed NOW.

  4. Send them back NOW.

  5. deport now

ADVERTISEMENT